A Phase II Study of Venetoclax (ABT-199) in Combination with Cladribine and Low-Dose Cytarabine Alternating with Azacitidine Plus Venetoclax in Newly Diagnosed Monocytic AML and Active-Signaling Mutated AML
Latest Information Update: 12 Mar 2025
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Cladribine (Primary) ; Cytarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
Most Recent Events
- 20 Jan 2025 Status changed from not yet recruiting to recruiting.
- 22 Jul 2024 New trial record